Abstract
Comprehending the mechanism behind human diseases with an established heritable component represents the forefront of personalized medicine. Nevertheless, numerous medically important genes are inaccurately represented in short-read sequencing data analysis due to their complexity and repetitiveness or the so-called ‘dark regions’ of the human genome. The advent of PacBio as a long-read platform has provided new insights, yet HiFi whole-genome sequencing (WGS) cost remains frequently prohibitive. We introduce a targeted sequencing and analysis framework, Twist Alliance Dark Genes Panel (TADGP), designed to offer phased variants across 389 medically important yet complex autosomal genes. We highlight TADGP accuracy across eleven control samples and compare it to WGS. This demonstrates that TADGP achieves variant calling accuracy comparable to HiFi-WGS data, but at a fraction of the cost. Thus, enabling scalability and broad applicability for studying rare diseases or complementing previously sequenced samples to gain insights into these complex genes.
TADGP revealed several candidate variants across all cases and provided insight into LPA diversity when tested on samples from rare disease and cardiovascular disease cohorts. In both cohorts, we identified novel variants affecting individual disease-associated genes (e.g., IKZF1, KCNE1). Nevertheless, the annotation of the variants across these 389 medically important genes remains challenging due to their underrepresentation in ClinVar and gnomAD. Consequently, we also offer an annotation resource to enhance the evaluation and prioritization of these variants.
Overall, we can demonstrate that TADGP offers a cost-efficient and scalable approach to routinely assess the dark regions of the human genome with clinical relevance.
Competing Interest Statement
FS received support from Illumina, Genentech, PacBio, and Oxford Nanopore Technologies. JH, XC, CL, SZ, PB, ME, SK, GH, and ZK are PacBio employees and shareholders. HC, TH, CR, and TF are employees of Twist.
Funding Statement
FJS and MM are supported by NIH grants (1U01HG011758-01). SIH S10 grant 1S10OD028587. We would like to thank Luis F. Paulin for his fruitful discussion on the de novo SVs calling. We would like to thank Barbara Bock for her help on gene annotations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Baylor College of Medicine (BCM) gave ethical approval for the rare disease patients under the protocol H-29697. Regarding the cardiovascular samples, the study was approved by the Baylor College of Medicine (BCM) Institutional Review Boards (protocol number: H-43884). Written informed consent was obtained from all study participants. All sample names have been deidentified.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Supplementary Table S7 lists the raw reads were downloaded from SRA The GIAB benchmark is downloadable here:
HG001:
SNVs and Indels: https://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/NA12878_HG001/latest/GRCh38/
HG002:
SNVs and Indels: https://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/AshkenazimTrio/HG002_NA24385_son/CMRG_v1.00/GRCh38/SmallVariant/
HG003:
HG004:
HG005:
HG006:
HG007:
ClinVar VCF file is available here: https://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh38/archive_2.0/2023/clinvar_20230107.vcf.gz
Variant calling VCF files are available at: https://doi.org/10.5281/zenodo.10806570
